Phase 1 Patient 1080-001:
Long Lasting Benefit in mCRC >5 years!

PET/CT before BXQ-350

PET/CT before BXQ-350

PET/CT before BXQ-350

PET/CT after 18 months on BXQ-350
  • 40-yr old female with stage 4 metastatic colorectal carcinoma
  • Diagnosed in Nov 2015, previously treated with surgery, chemotherapy and radiation (>3 lines)
  • Rapid progression (5 months) prior to starting BXQ-350
  • Target lesion (1.5 cm) remained unchanged per Recist
  • Still Stable Disease over 5 years on study

Phase 1 Patient 1008-701:
Long Lasting Benefit in GBM > 5 years!

Screening

Day 56

Day 56 Screening
  • Red Arrows indicate the initial target lesion that decreased in size while on study
  • Blue Arrows indicate new area of enhancement

Note: Surgery in May, 2018 revealed significant treatment effect with only trace tumor cells present. As of September, 2019 patient continues on study having completed 3 years in the trial.

Case Data: Glioblastoma (GBM)

Axial T1-post contrast (Ax SE T1 POST FC) 1.5T MRI of the brain of a 64-yr old male patient with glioblastoma (GBM) treated with BXQ-350. GBM was first diagnosed in 2013 and previously treated with surgery, chemotherapy and radiation. Measurable lesion reduction over time is apparent in the anterior corpus callosum and frontal lobe, with those bordering the ventricle.

Phase 1 Patient 1075-213:
Partial Response in Glioblastoma (-74%)

Screening

Day 56

Day 56 Screening
  • 65-yr old female with rGBM
  • GBM diagnosed in March 2017 (stage IV) previously treated with surgery, chemotherapy and radiation
  • Rapid progression (2M) prior to starting BXQ-350 in May 2018
  • 1 target lesion (L parietal) 1.4 cm at Screening down to 0.36 cm at Day 56 (-74%)
  • Progressed after 948 days on BXQ-350